Paul Mahon Sells 8,300 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) EVP Paul Mahon sold 8,300 shares of the company’s stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $483.16, for a total transaction of $4,010,228.00. Following the transaction, the executive vice president directly owned 36,844 shares of the company’s stock, valued at $17,801,547.04. This represents a 18.39% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

United Therapeutics Stock Performance

NASDAQ UTHR opened at $478.16 on Friday. United Therapeutics Corporation has a twelve month low of $266.98 and a twelve month high of $537.19. The stock has a market cap of $20.96 billion, a PE ratio of 17.14, a PEG ratio of 1.75 and a beta of 0.84. The firm has a 50-day simple moving average of $482.51 and a 200 day simple moving average of $452.28.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.78 by $0.92. The firm had revenue of $790.20 million for the quarter, compared to analyst estimates of $814.80 million. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The company’s quarterly revenue was up 7.4% compared to the same quarter last year. During the same period in the previous year, the company posted $6.19 earnings per share. Research analysts forecast that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

United Therapeutics News Roundup

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: UBS raised its price target on UTHR from $655 to $705 and kept a Buy rating — a notable analyst endorsement implying material upside that could attract buyers. Read More.
• Neutral Sentiment: Multiple sell‑side firms have recently increased targets and reiterated Buy/outperform views (Oppenheimer, HC Wainwright, TD Cowen); consensus remains a “Moderate Buy” with a mid‑range price target, supporting a constructive medium‑term thesis. Read More.
• Negative Sentiment: A wave of insider selling this week is pressuring sentiment: CEO Martine Rothblatt sold 9,500 shares (~$4.65M), and several directors/executives (Ray Kurzweil, Paul Mahon, Tommy G. Thompson and others) also sold blocks at roughly $483–$490 per share. These large, concentrated disposals can prompt near‑term weakness even if insiders retain stakes. Read More. Read More.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of UTHR. Avoro Capital Advisors LLC raised its position in shares of United Therapeutics by 17.3% during the fourth quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock worth $1,269,803,000 after acquiring an additional 383,838 shares during the last quarter. Wellington Management Group LLP lifted its stake in shares of United Therapeutics by 74.5% in the 4th quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock valued at $1,189,617,000 after purchasing an additional 1,042,711 shares during the period. AQR Capital Management LLC lifted its stake in shares of United Therapeutics by 29.9% in the 4th quarter. AQR Capital Management LLC now owns 1,281,699 shares of the biotechnology company’s stock valued at $624,508,000 after purchasing an additional 295,221 shares during the period. Invesco Ltd. boosted its position in shares of United Therapeutics by 90.2% in the 2nd quarter. Invesco Ltd. now owns 884,703 shares of the biotechnology company’s stock worth $254,219,000 after purchasing an additional 419,588 shares during the last quarter. Finally, Janus Henderson Group PLC boosted its position in shares of United Therapeutics by 75.1% in the 4th quarter. Janus Henderson Group PLC now owns 796,101 shares of the biotechnology company’s stock worth $387,801,000 after purchasing an additional 341,383 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research analysts recently commented on UTHR shares. HC Wainwright upped their target price on United Therapeutics from $525.00 to $600.00 and gave the company a “buy” rating in a research note on Thursday, February 26th. Jefferies Financial Group reissued a “buy” rating on shares of United Therapeutics in a report on Monday. TD Cowen increased their price objective on shares of United Therapeutics from $525.00 to $575.00 and gave the company a “buy” rating in a research note on Wednesday, February 25th. Royal Bank Of Canada raised their price objective on shares of United Therapeutics from $587.00 to $643.00 and gave the stock an “outperform” rating in a report on Thursday, February 26th. Finally, Weiss Ratings reissued a “buy (b)” rating on shares of United Therapeutics in a report on Monday, December 29th. Nine research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, United Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $539.00.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.